Navigation Links
New role for Tamoxifen in saving high-risk breast cancer patients
Date:8/7/2013

The global study was led by University of Melbourne and the Peter MacCallum Cancer Centre and published in the Journal of Clinical Oncology today.

The study involved about 2,500 women from Europe, North America and Australia who have inherited mutations in BRCA1 or BRCA2, the breast cancer susceptibility genes, and who had been diagnosed with breast cancer. About one-third of these women were placed on tamoxifen.

Tamoxifen has been used for decades to treat breast cancer and has recently been shown to prevent breast cancers in many women.

Until now, there has been limited information about whether it reduces breast cancer risk for women who are at the very highest level of risk with BRCA1 or BRCA2.

Lead author, Professor Kelly-Anne Phillips says this study, the largest to date, suggests that it could work for these high-risk women by halving their breast cancer risk.

"In the past, the only way of reducing breast cancer risk for these high-risk women was to do invasive surgery to remove their breasts and/or ovaries. For women who choose not to undergo such surgery, or who would prefer to delay surgery until they are older, tamoxifen could now be a viable alternative."

Such was the case for US actress Angelina Jolie who was found to carry a mutation in one of these genes.

Previous research led by Professor Phillips revealed that only 1 in 5 Australian women with a mutation in BRCA1 or BRCA2 choose to undergo bilateral mastectomy to prevent cancer.

Professor John Hopper, co-author from the School of Population and Global Health at the University of Melbourne, says "In light of our findings, it is clear that women who have a mutation in BRCA1 or BRCA2 should review their management plan with their specialist and re-discuss the options available to them to lower that risk."

This important finding has come from more than 20 years of research involving breast cancer families recruited from cancer registries and clinics across the country.

"Without the generous contributions of those families we would not be able to make such discoveries which help future generations fight breast cancer," he says.


'/>"/>

Contact: Anne Rahilly
arahilly@unimelb.edu.au
61-390-355-380
University of Melbourne
Source:Eurekalert

Related medicine news :

1. Possible therapy for tamoxifen resistant breast cancer identified
2. New finding gives clues for overcoming tamoxifen-resistant breast cancer
3. 10 Years of Tamoxifen Better Than 5: Study
4. Tamoxifen trial should prompt breast cancer patients to reconsider treatment options
5. Ability to metabolize tamoxifen affects breast cancer outcomes, Mayo Clinic-led study confirms
6. Genes Linked to Effectiveness of Tamoxifen for Breast Cancer
7. Researchers identify new pathway, enhancing tamoxifen to tame aggressive breast cancer
8. Doubling Time on Tamoxifen Cuts Odds for Breast Cancers Return: Study
9. Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment
10. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
11. National poll: Low cost, lifesaving services missing from most older patients health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Utah (PRWEB) , ... February 28, 2017 , ... ... held Overl.ai Inc., a healthcare automation intelligence company based in New York. , ... is ensuring the provider’s workflow remains unaltered. Those two fundamental reasons are the ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and overall body strength, which often leads to a host of health issues, ... of the American Geriatrics Society discovered that good overall muscle strength in ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear ... work for a company involved in the underground testing of nuclear weapons. Years later, ... Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... Morristown, New Jersey (PRWEB) , ... February 27, 2017 , ... ... the highest cancer rates, among all types and genders. And the need for advanced ... led by RWJ and its top-rated cancer care program, in collaboration with their non-profit ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 28, 2017 ... Research and Markets has announced the ... 2025" report to their offering. The global ... of USD 239.8 billion by 2025. The rising prevalence of lifestyle-induced ... over the forecast period. Advancements in recombinant molecular technologies and high ...
(Date:2/28/2017)... , Feb. 28, 2017  Rigel Pharmaceuticals, Inc. ... it will report its fourth quarter and year ... March 7, 2017.  Rigel senior management will follow ... webcast at 5:00pm Eastern Time (2:00pm Pacific Time) ... can access the live conference call by dialing ...
(Date:2/28/2017)... SOUTH SAN FRANCISCO, Calif. , Feb. 27, ... company developing proprietary therapeutics for the treatment of ... drug delivery platform, today announced that the U.S. ... initial review of the ropinirole implant Investigational New ... hold the initiation of the clinical study pending ...
Breaking Medicine Technology: